Our ability to provide a multi-faceted approach to formulation and cGMP compliance is of critical value to our customers as there are many unknowns through all the stages of the product development process. With extensive experience in research, formulation, analytics and advanced manufacturing, our world-class scientific team understands the challenges and complexities of providing regulatory conforming clinical materials.
The SARS-CoV2 pandemic highlighted the need for proven and effective approaches to vaccine development. It is important to note that USSF has been working in partnership with Vaxform to develop vaccines since its inception in 2013.
USSF Vaccine Products
- SARS‐CoV‐2 oral vaccine (pre-clincal)
- Group A Strep injectable vaccine
- Pertussis (Whooping Cough) oral vaccine
USSF to Manufacture Oral Covid-19 Vaccine for 2021 Distribution
On December 3, 2020, a Zoom press conference held by the Pennsylvania Department of Community and Economic Development (DCED) announced a funding commitment to US Specialty Formulations (USSF) to scale up for production of an oral Covid-19 vaccine for 2021 distribution.Read More